Inmune Bio, Inc. entered into Amended and Restated Material Transfer and License Agreement with Anthony Nolan valued at an annual cap of £5,000,000 (effective 2026-04-29).
“On April 29, 2026, INmune Bio Inc. (the “Company”) entered into an amended and restated Material Transfer and License Agreement (the “ Amended and Restated Agreement ”) with INmune Bio International (“ IMB ”), a company incorporated in England and the Company’s wholly-owned subsidiary, and Anthony Nolan (“ AN ”), a company limited by guarantee incorporated in England, which amended and restated the original agreement signed by IMB and AN on November 29, 2017, as amended and restated on March 21, 2023 (the “ Original Agreement ”).”
Material Agreements
Inmune Bio, Inc. amended Warrant Amendment with certain holders of warrants previously issued by the Company valued at $0.05 per April 2024 Warrant, for aggregate proceeds of $67,416 (effective 2025-12-22).
“On December 22, 2025, INmune Bio Inc. (the “Company”) entered into an amendment (the “Warrant Amendment”) with certain holders of warrants previously issued by the Company in its April 2024 offerings”
Edgardo Baracchini resigned as Director at Inmune Bio, Inc..
“On July 5, 2024, Edgardo Baracchini informed INmune Bio Inc. (the “Company”) of his resignation from the board of directors of the Company (the “Board”), effective immediately.”
Material Agreements
Inmune Bio, Inc. entered into Placement Agency Agreement with Maxim Group LLC valued at 6% cash fee of gross proceeds (effective 2024-04-24).
“Pursuant to a placement agency agreement (the “Placement Agency Agreement”) dated as of April 24, 2024, between the Company and Maxim Group LLC (the “Placement Agent”), the Company engaged the Placement Agent to act as the Company’s sole placement agent in connection with the registered direct offering.”
Material Agreements
Inmune Bio, Inc. entered into Securities Purchase Agreement with Purchasers valued at 986,000 shares of common stock and warrants at $9.84 per share, aggregate gross proceeds $9,702,240 (effective 2024-04-24).
“On April 24, 2024, INmune Bio, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the purchaser set forth on the signature page thereto (the “Purchasers) for the purchase and sale of an aggregate of 986,000 shares of the Company’s common stock (the “Shares”) and common stock warrants to purchase 986,000 shares of its common stock (“Warrants”) in a registered direct offering.”
Material Agreements
Inmune Bio, Inc. entered into Placement Agency Agreement with LifeSci Capital LLC valued at Cash fee equal to 4% of gross proceeds from sale of shares and warrants (effective 2024-04-19).
“Pursuant to a placement agency agreement (the “Placement Agency Agreement”) dated as of April 19, 2024, between the Company and LifeSci Capital LLC (the “Placement Agent Agreement,” the Company engaged the Placement Agent to act as the Company’s sole placement agent in connection with the registered direct offering.”
Material Agreements
Inmune Bio, Inc. entered into Securities Purchase Agreement with Purchasers valued at 571,592 shares of common stock and warrants to purchase 571,592 shares at $8.32 per share and warran (effective 2024-04-19).
“On April 19, 2024, INmune Bio, Inc. (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers set forth on the signature page thereto (the “Purchasers”) for the purchase and sale of an aggregate of 571,592 shares of the Company’s common stock (the “Shares”) and common stock warrants to purchase 571,592 shares of its common stock (“Warrants”) in a registered direct offering.”
Earnings Releases
Inmune Bio, Inc. reported the year ended December 31, 2023 results: net income approximately $30.0 million.
“Net loss attributable to common stockholders for the year ended December 31, 2023, was approximately $30.0 million, compared to approximately $27.3 million during the year ended December 31, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.